Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with
 acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the
 safety and tolerability of SOMAVERT.
Inclusion Criteria:

 -  Subjects must have participated and completed the previous Pegvisomant studies or have
 shown to be unresponsive to other conventional therapies

 Exclusion Criteria:

 -  ALT/AST>3 times the ULN or have hepatic disease

 -  have severe visual field loss, cranial nerve palsies or intracranial HTN that requires
 surgery to decompress the tumor

 -  unwilling to self-administer the medication.